← Leaderboards
Ya-Wen Chen
University Of Southern California
$3,420,582
Attributed
$3,899,581
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,899,581 · 3
By mechanism
R01$3,478,362 · 2
R56$421,219 · 1
Top collaborators
- Valerie Copie1 shared
- Nadja Zeltner1 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Biju Blavady Thomas$2,504,248
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroCellsOrganoidsResponse3-DimensionalHuman Pluripotent Stem CellInsightMolecularTissuesStem CellsCovid-19 TreatmentDrug CandidateAlveolar Type Ii CellAnimal ModelCytotoxicityEfficacy EvaluationEfficacy TestingCessation Of LifeBinding ProteinsBindingCell SurvivalCell TypeAce22019-Ncov
Grant awards (6)
Using 2D and 3D adrenal gland tissues to investigate developmental and disease paradigms$718,499
R01 · FY2025 · HD
TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung$710,591
R01 · FY2025 · HL · contact PI
TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung$638,230
R01 · FY2024 · HL · contact PI
TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung$705,521
R01 · FY2023 · HL · contact PI
TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung$705,521
R01 · FY2022 · HL · contact PI
TMPRSS2 as a potential target for treatments of COVID-19 and respiratory infectious viruses in lung$421,219
R56 · FY2021 · HL · contact PI